RxDoctor Payments Data

Deborah Hodge

Nurse Practitioner · Houston, TXNPI 1821172990

Payments from drug & device makers

$2,993in general payments, 2019–2025

Across 141 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$471
  • Mylan Specialty L.p.$355
  • Lilly USA, LLC$336
  • GSK$223
  • Bayer$207
  • Sanofi$176
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,993 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$82,371
Medicare patients
334
Services billed
2,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$57,765
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$34,652
EliquisApixaban28$23,815
JardianceEmpagliflozin11$13,749
FarxigaDapagliflozin Propanediol14$9,059
LinzessLinaclotide12$7,272
Rosuvastatin Calcium136$2,826
Atorvastatin Calcium241$2,543
Albuterol Sulfate HfaAlbuterol Sulfate95$2,398
SynthroidLevothyroxine Sodium27$2,082
Metoprolol Succinate80$1,760
Olmesartan Medoxomil59$1,639
Losartan Potassium141$1,573
Gabapentin119$1,458
Levothyroxine Sodium146$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$471$57,76538 claims
GSKTrelegy Ellipta$223$34,65232 claims
PfizerEliquis$79$23,81528 claims
Boehringer IngelheimJardiance$17$13,74911 claims
AbbVieLinzess, Synthroid$47$9,35439 claims
AstraZenecaFarxiga$130$9,05914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →